R&D
Research and Development
Summary
Optipharm
Corporate-affiliated Research Institute
| Founding Date | 17th Nov. 2011 |
| Research Institute Accreditation NO. | NO. 2011210512 |
| Certification of Excellent Corporate-Affiliated Research Institute |
25th Nov. 2021 |
We realize healthy and happy companionship between Human and Animals
by suggesting new standard for Bio Healthcare.
Since Optipharm was certified as a corporate-affiliated research institute in 2011, it has been engaged in a range of R&D to promote human health, mainly in the field of life sciences.
Transgenic Animal Development Team
- Transgenic cell line development
- Development of transgenic Minipig
- R&D related to xenogenic organs
- Research and management of government projects
Vaccine
Development Team
- R&D of VLP vaccine for animals
- R&D of VLP vaccine for human body
- Research and management of government projects
- Technology transfer implementation
Features of Optipharm’s Technology
-
01Possession and utilization of original technology
- Diagnosis of animal diseases
- VLP expression system based on insect cells
- Transgenic minipig
-
02Application of next generation technology
- Microbiome
- Bacteriophage
- Genetic scissors, etc.
-
03High value-added human care
- HPV
- Xenogenic islets
- MRAB
-
04Open innovation
- ToolGen
- Genome & Company, etc.
Introduction of Major Researchers
Optipharm's research institute consists of approximately 30 researchers, most of whom
are experts who have completed master's and/or doctoral degrees.
* Doctor's degree 11 people, Master's degree 20 people, etc. (2021)
Choi Kimyung
Director
Transgenic
- Doctor of Animal Breeding and Reproduction Science,
Chungnam National University
- Employment period : Feb 2012. ~ present
Han Bumgu
Director
VLP Vaccine
- Ph.D., Department of Biotechnology, Ajou University
Engineering Research Center, Ajou University
- Employment period : Mar 2001. ~ present